Biocon

“Biocon Group’s overall #Q2FY25 financial and operational performance provides a foundation for improved performance as we move into the second half of the fiscal. Reported Operating Revenues of Rs 3,590 Cr reflect YoY growth of 8% on a like for like basis and core EBITDA and EBITDA margins of 28% and 20% respectively remain healthy. We had a robust performance in the Biosimilars business, up 19% on a like for like revenue basis, driven by strong market share gains in our US Oncology and Insulins franchises. Syngene has returned to sequential growth and has good visibility of a pickup in momentum in the coming quarters led by its Discovery Services and Biomanufacturing CMO business. Generics has continued to face price and demand pressures that have suppressed performance, but key new formulation launches in Q3 and Q4 provide the basis of a turnaround before the year end. All three businesses are tracking towards a better performance in the second half of the year, on the back of product approvals and unfolding market opportunities. “Biocon Biologics’ successful refinancing of its long-term debt of US$ 1.1 billion through a combination an $800 million USD bond listed on the Singapore Stock Exchange and a new $300 million syndicated loan facility was a credible success. This was Biocon Group’s debut bond issue and to be 3x oversubscribed speaks to strong investor confidence in our Biosimilars growth potential.” Kiran Mazumdar Shaw, Chairperson, Biocon Group. said on #Q2FY25 results. Read more: https://bit.ly/PRP20241030

“With like for like Operating Revenue growth of 8%, Biocon Group’s consolidated performance in Q2FY25 was balanced and in line with our expectations. Healthy double-digit growth in Biosimilars more than offset a relatively muted performance in the Generics business and a marginal decline in Syngene’s revenues. Reported Net Loss for the quarter was Rs 16 Cr on account of higher tax, based on geographical split of profits and minority interest. Adjusting for exceptional items, the loss stands at Rs 13 Cr. “We maintain our outlook for a transition to accelerating growth in the second half of the year with Syngene returning to growth, building momentum in our Biosimilars business and a recovery in Generics in the latter part of H2 driven by the launch of our first GLP-1 generic in the UK. The highly successful Biocon Biologics bond issue was a standout achievement and has significantly strengthened its mid-term financial foundation.” Peter Bains, Group CEO, Biocon Limited. comments on #Q2FY25 results. Read more: https://bit.ly/PRP20241030

“The Generics business continues to face pricing pressure and demand contraction. This quarter we also carried out a planned shut-down of one of our API facilities, which further impacted revenues. We received a few drug product approvals in the U.S., UK, EU and MoW markets, which will support our near-term sales. The licensing agreements signed with two leading pharmaceutical companies in the Middle East and Brazil, for the commercialization of our GLP-1 products will enable mid and long-term growth in these regions.   “As stated earlier, we expect a transition to growth in the second half of this fiscal on the back of new product launches, including Liraglutide in the UK, as well as other injectable products, such as Micafungin and Daptomycin.”     Siddharth Mittal, CEO & Managing Director, Biocon Limited. on #Q2FY25 results. Read more: https://bit.ly/PRP20241030

#Press: #Biocon's Operating Revenue for #Q2FY25 Up 8% at Rs 3,590 Cr Core EBITDA at Rs 992 Cr, margins at 28%; EBITDA at Rs 718 Cr, margins at 20% Read more: https://bit.ly/PRP20241030

Insights from a fireside chat with our Head - Global API Commercials & FDF - Emerging Markets, Amit Kaptain on Walking the Talk, one of the five behavioral pillars at #Biocon, that enables employees to push the frontiers of what is possible.

Biocon continues its legacy of excellence, ranking No. 9 on Science Magazine's 2024 Top Global Employers list! Recognized for over a decade as an ‘Innovative Leader in the Industry,’ #Biocon’s commitment to #science and social responsibility positions it as a premier biotech employer. Read more: https://bit.ly/PR20241028 #BioconTop10 #SCTopEmployers #biotech #pharma #biopharma

Excited to announce that Biocon Chairperson Kiran Mazumdar Shaw has been honored with the IKP@25 Shapers Award at #IKMC2024 for her invaluable and steadfast support of over 25 years to IKP Knowledge Park which has been a driving force in shaping India's #innovation landscape.

Alert: Seats are filling fast! If you are ready to make your mark, here’s your moment— admissions for Batch 28 of the Biocon KGI Certificate in Biosciences are open. To apply, click https://bit.ly/4gcBjM0 For more information, click https://bit.ly/3Zu1Ez8 #admissions #applynow #biosciences #biotechnology #biochemistry #careers #engineers #freshers #genetics #lifesciences #microbiology #opportunities #pharmacy #technology

Thank you, Central Drugs Standard Control Organization for inviting Biocon to be part of the 19th International Conference of Drugs Regulatory Authorities event in New Delhi. It was an engaging and insightful two days of meeting and interacting with officials of regulatory authorities from across the globe. We appreciated the interactions and exchanges towards our common objective of strengthening quality and streamlining regulatory processes. #ThisisBiocon #ICDRA #CDSCO #RegulatoryAffairs

We are proud to share that #BioconFoundation has been honored with the prestigious ‘Doing Good for Bharat Awards 2024’ in the Healthcare Category for its pioneering work with eLAJ Smart Clinics! This recognition reflects our commitment to reimagining healthcare for underserved communities. Since its launch in 2016, #eLAJ Smart Clinics have reached over 1 million people across Karnataka, with 3.4 lakh unique patient visits. We thank CSR Box and the esteemed jury for acknowledging our efforts towards making quality healthcare accessible for all. Read more: bit.ly/PRP20241025